Osaka, Japan, December 2nd, 2025 - Luxna Biotech Co., Ltd. (President CEO: Hideaki Sato; Headquarters: Suita-shi, Osaka, Japan, hereinafter “Luxna”) and one of the largest contract development and manufacturing organizations (CDMO) specializing in oligonucleotide therapeutics, BioSpring GmbH (CEO: Dr. Sylvia Wojczewski; Headquarters: Frankfurt am Main, Germany, hereinafter “BioSpring”) announced a new collaboration.
In this new project, Luxna will advance an oligonucleotide therapeutic for an undisclosed target, while BioSpring contributes its expertise in process development, analytical characterization, and clinical manufacturing of oligonucleotides.
This expands the recently announced partnership between Luxna and BioSpring, furthering the translation of Luxna’s proprietary XNA amidite chemistry into therapeutic oligonucleotides.
Supporting Luxna not only in manufacturing, but also in the development and scale-up of complex oligonucleotide candidates underscores BioSpring’s role as an enabler for innovative biotech and pharma programs. Together, Luxna and BioSpring aim to accelerate the path from concept to clinic and ensure reliable supply for future clinical and commercial needs.
Mr. Hideaki Sato, President and CEO, Luxna Biotech:
“This project marks the next step in translating Luxna’s XNA technology into therapeutic development. Together with BioSpring, we are accelerating the path toward clinical application while reinforcing our commitment to bringing new treatment options to patients.”
Dr. Sylvia Wojczewski, CEO, BioSpring:
We are proud that Luxna has selected BioSpring to support its therapeutic programs based on its XNA technology. This technology presents novel opportunities for advancement in therapeutic innovation in the oligonucleotide field.
About Luxna XNAs Technology
Luxna XNAs Technology collectively means an innovative nucleic acid group of AmNA™, scpBNA™, GuNA™ and 5’-CP™ originated in Professor Obika’s laboratory at the Osaka University Graduate School of Pharmaceutical Sciences, Bioorganic Chemistry. Luxna XNAs Technology could make available ASOs with high activity and low toxicity, by taking advantage of its characteristics of strong binding to mRNA and/or reduced immune response.
About Luxna Biotech
Luxna is a biotech founded to develop safer and more effective oligonucleotide
therapies (OTs) for practical use using the drug discovery platform, called
LuxiAP™, based on modified nucleic acids originated in Professor Obika’s
laboratory at Osaka University Graduate School of Pharmaceutical Sciences,
Bioorganic Chemistry at Osaka University. Our purpose is to bring OTs for
patients with difficult-to-treat diseases. We actively collaborate with several
pharmaceutical companies in developing new and effective OTs as well as
advancing our own.
About BioSpring
BioSpring is a globally leading contract manufacturer of oligonucleotides, with
a strong focus on therapeutic oligonucleotides. Founded in 1997, the company
partners with biotech and pharmaceutical companies worldwide throughout the
entire drug development lifecycle, from early research to commercial
manufacturing. The company has been GMP-inspected since 2007 and FDA-inspected
since 2016, underscoring its long-standing commitment to quality. BioSpring is
currently expanding its production capacities with a new large-scale facility
in Offenbach am Main, designed to meet growing global demand for advanced
nucleic acid therapeutics.
Contact
Luxna Biotech Co., Ltd.
E-mail: info@luxnabiotech.co.jp; Website: https://luxnabiotech.co.jp/
BioSpring GmbH
